Clinical Trial Detail

NCT ID NCT04003610
Title Pemigatinib + Pembrolizumab vs Pemigatinib Alone vs Standard of Care for Urothelial Carcinoma (FIGHT-205)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Incyte Corporation
Indications

transitional cell carcinoma

Therapies

Pembrolizumab + Pemigatinib

Pembrolizumab

Carboplatin + Gemcitabine

Pemigatinib

Age Groups: senior adult

Additional content available in CKB BOOST